Acne guideline 2005 update

South African Medical Journal

Volumn 95, Issue 11 II, 2005, Pages 883-892

  Sinclair, Werner ^a   Jordaan, H Francois ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADAPALENE; ANTI ACNE AGENT; ANTIANDROGEN; ANTIBIOTIC AGENT; AZELAIC ACID; BENZOYL PEROXIDE; CLINDAMYCIN; COTRIMOXAZOLE; CYPROTERONE ACETATE; DAPSONE; DOXYCYCLINE; DROSPIRENONE; ERYTHROMYCIN; ETHINYLESTRADIOL; ISOTRETINOIN; LYMECYCLINE; MINOCYCLINE; ORAL CONTRACEPTIVE AGENT; OXYTETRACYCLINE; PENICILLIN DERIVATIVE; PREDNISONE; RETINOIC ACID; RETINOID DERIVATIVE; RETINOL; SALICYLIC ACID; SPIRONOLACTONE; TAZAROTENE; TETRACYCLINE DERIVATIVE; UNINDEXED DRUG; ZINC ACETATE; ANTIINFECTIVE AGENT; RETINOID;

ACNE VULGARIS; ANEMIA; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTHRALGIA; BONE DISEASE; CALCIFICATION; CLINICAL PRACTICE; CONSENSUS DEVELOPMENT; DEPRESSION; DERMATOLOGY; DIAGNOSTIC TEST; DIGESTIVE SYSTEM FUNCTION DISORDER; DISEASE EXACERBATION; DRUG COST; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG MECHANISM; DRUG POTENTIATION; DRY SKIN; EVIDENCE BASED MEDICINE; HAIR LOSS; HEADACHE; HEALTH CARE PERSONNEL; HUMAN; HYPEROSTOSIS; HYPERPIGMENTATION; HYPERSENSITIVITY REACTION; HYPERTRIGLYCERIDEMIA; INTRACRANIAL HYPERTENSION; LIVER DYSFUNCTION; MAINTENANCE THERAPY; MEDICAL EXPERT; MEDICAL LITERATURE; MEDICAL SOCIETY; MEDICAL SPECIALIST; MYALGIA; NIGHT BLINDNESS; NONHUMAN; OSTEOPOROSIS; PATHOPHYSIOLOGY; PHOTOSENSITIVITY; PHOTOTOXICITY; PRACTICE GUIDELINE; PROPIONIBACTERIUM ACNES; QUALITY OF LIFE; REVIEW; SERUM SICKNESS; SKIN IRRITATION; SOUTH AFRICA; SPINE DISEASE; SUICIDE; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT OUTCOME; TREATMENT PLANNING; CLASSIFICATION; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG COMBINATION; SKIN CARE;

ACNE VULGARIS; ANDROGEN ANTAGONISTS; ANTI-BACTERIAL AGENTS; BENZOYL PEROXIDE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, BACTERIAL; DRUG THERAPY, COMBINATION; HUMANS; ISOTRETINOIN; RETINOIDS; SKIN CARE;

EID: 28044451329     PISSN: 02569574     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (64)

1. Cunliffe WJ, Gould DJ. Prevalence of facial acne vulgaris in late adolescence and in adults. BMJ 1979; 1: 1109-1110.
2. Picardi A. Abeni D, Melchi CF, Puddu P, Pasquini P. Psychiatric morbidity in dermatological outpatients: an issue to be recognized. Br J Dermatol 2000; 143: 983-991.
3. Mallon E, Newton JN, Klassen A, Stewart-Brown SL, Ryan TJ, Finlay AY. The quality of life in acne: a comparison with general medical conditions using generic questionnaires. Br J Dermatol 1999; 140: 672-676.
4. Cunliffe WJ. Acne and unemployment. Br J Dermatol 1986; 115: 386.
5. Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI) - a simple practical measure for routine clinical use. Clin Exp Dermatol 1994; 19: 210-216.
6. Kellet SC, Gawkrodger DJ. The psychological and emotional impact of acne and the effect of treatment with isotretinoin. Br J Dermatol 1999; 140: 273-282.
7. Gollnick HPM, Zouboulis CC, Akamatsu H, et al. Pathogenesis and pathogenesis-related treatment of acne. J Dermatol 1991; 18: 489-499.
8. Thiboutot D, Knaggs H, Gilliland H, et al. Activity of 5-α-reductase and 17-β-hydroxysteroid dehydrogenase in the infraindibulum of subjects with and without acne vulgaris. Dermatology 1998; 196: 38-42.
9. Thiboutot DM, Knaggs H, Gilliland K, et al. Activity of type 1 5α-reductase is greater in the follicular infrainfundibulum compared with the epidermis. Br J Dermatol 1997; 136: 166-171.
10. Fritsch M, Orfanos CE, Zouboulis CC. Sebocytes are the key regulators of androgen homeostasis in human skin. J Invest Dermatol 2001; 116: 793-800.
11. Cunliffe WJ, Holland DB, Clark SM, et al. Comedogenesis: some new aetiological, clinical an therapeutic strategies. Br J Dermatol 2000; 142: 1084-1091.
12. Webster GF, Leyden JJ, Musson RA, Douglas SD. Susceptibility of Propionibacterium acnes to killing and degradation by human neutrophils and monocytes in vitro. Infect Immun 1985; 49(1): 116-121.
13. Cove JH, Holland KT, Cunliffe WJ. An analysis of sebum excretion rate, bacterial population and the production rate of free fatty acids on human skin. Br J Dermatol 1980; 103: 383-386.
14. Leeming JP, Holland KT, Cunliffe WJ. The microbial colonization of inflamed acne vulgaris lesions. Br J Dermatol 1988; 118: 203-208.
15. Leyden JJ, McGinley KJ, Mills OH, Kligman AM. Age-related changes in the resident bacterial flora of the human face. J Invest Dematol 1975; 65: 379-381.
16. McGinley KJ, Webster GF, Ruggieri MR, Leyden JJ. Regional variations in density of cutaneous propionibacteria: correlation of Propionibacterium acnes with sebum secretion. J Clin Microbiol 1980; 12: 672-675.
17. Webster GF, Tsai C-C, Leyden JJ. Neutrophil lysosomal release in response to Propionibacterium acnes (abstract). J Invest Dermatol 1979; 72: 209.
18. Ingham E, Eady EA, Goodwin CE. Pro-inflammatory levels of interleukin-1 like bioactivity are present in the majority of open comedones in acne vulgaris. J Invest Dermatol 1992; 98: 895-901.
19. Ashbee HR, Muir SR, Cunliffe WJ, Ingham E. IgG subclasses specific to Staphylococcus epidermidis and Propionibacterium acnes in patients with acne vulgaris. Br J Dermatol 1997; 136: 730-735.
20. Holland KT, Aldana O, Bojar RA, et al. Propionibacterium acnes and acne. Dermatology 1998; 196: 67-68.
21. Jappe U, Ingham E, Henwood J, Holland KT. Propionibacterium acnes and inflammation in acne; P. acnes has T-cell mitogenic activity. Br J Dermatol 2002; 146: 202-208.
22. Cunliffe WJ, Aldana OL, Goulden V. Oral trimethoprim: a relatively safe and successful third-line treatment for acne vulgaris. Br J Dermatol 1999; 141: 757-758.
23. Eady EA, Cove JH. Is acne an infection of blocked pilosebaceous follicles? Implications for antimicrobial treatment. Am J Clin Dermatol 2000; 1: 201-209.
24. Ianaro A, Ialenti A, Maffia P, et al. Anti-inflammatory activity of macrolides antibiotics. J Pharmacol Exp Ther 2000; 292(1): 156-163.
25. Brinkmeier T, Frosch PJ. Orale Antibiotika mit antiinflammatorischer/immunmodulatorischer Wirkung für die Therapie verschiedener Dermatosen. Der Hautarzt 2002; 53: 456-465.
26. Humbert P, Treffel P, Chapuis JF, Buchet S, Derancourt C, Agache P. The tetracyclines in dermatology. J Am Acad Dermatol 1991; 25: 691-697.
27. Wales D, Woodhead M. The anti-inflammatory effects of macrolides. Thorax 1999; 54: 58-62.
28. Tamaoki J, Kondo M, Kohri K, Aoshiba K, Tagaya E, Nagai A. Macrolide antibiotics protect against immune complex-induced lung injury in rats: Role of nitric oxide from alveolar macrophages. J Immunol 1999; 163: 2909-2915.
29. Leyden JJ, McGinley KJ, Cavalieri S, Webster GF, Mills OH, Kligman AM. Propionibacterium acnes resistance to antibiotics in acne patients. J Am Acad Dermatol 1983, 8(1): 41-45.
30. Eady EA, Cove JH, Holland KT, Cunliffe WJ. Erythromycin resistant Propionibacteria in antibiotic treated acne patients: association with therapeutic failure. Br J Dermatol 1989; 8: 41-45.
31. Bossuyt L, Bosschaert J, Richert B, et al. Lymecycline in the treatment of acne: an efficacious, safe and cost-effective alternative to minocycline. Eur J Dermatol 2003; 13(2): 130-135.
32. Gough A, Chapman S, Wagstaff K, Emery P, Elias E. Minocycline induced autoimmune hepatitis and systemic lupus erythematosus-like syndrome. BMJ 1996; 312: 169-172.
33. Sturkenboom MC, Meier CR, Jick H, et al. Minocycline and lupus-like syndrome in acne patients. Arch Intern Med 1999; 159: 493-497.
34. Gottlieb A. Safety of minocycline for acne. Lancet 1997; 349: 374.
35. Eichenfield, A. Minocycline and autoimmunity. Curr Opin Pediatr 1999; 11: 447-456.
36. Grosshans E, Belaich S, Meynadier J, et al. A comparison of the efficacy and safety of lymecycline and minocycline in patients with moderately severe acne vulgaris. Eur J Dermatol 1998; 8: 161-166.
37. Wolf JE Jr, Kaplan D, Kraus SJ, et al. Efficacy and tolerability of combined topical treatment of acne vulgaris with adepalene and clindamycin: A multicenter, randomized, investigator-blinded study. J Am Acad Dermatol 2003; 49: S211-217.
38. Shalita AR, Weiss JS, Chalker DK, et al. A comparison of the efficacy and safety of adapalene gel 0.1% and tretinoin gel 0.025% in the treatment of acne vulgaris: a multicenter trial. J Am Acad Dermatol 1996; 34: 482-485.
39. Cunliffe WJ, Poncet M, Loesche C, Verschoore M. A comparison of the efficacy and tolerability of adapalene 0.1% gel versus tretinoin 0.025% gel in patients with acne vulgaris: a meta-analysis of five randomized trials. Br J Dermatol 1998; 139: suppl 52, 48-56.
40. Dunlap FE, Mills OH, Turley MR, et al. Adapalene 0.1% gel for the treatment of acne vulgaris: its superiority compared to tretinoin 0.025% cream in skin tolerance and patient preference. Br J Dermatol 1998; 139: Suppl 2, 17-22.
41. Ozolins M, Eady EA, Avery AJ, et al. Comparison of five antimicrobial regimens for treatment of mild to moderate inflammatory facial acne vulgaris in the community. A randomized controlled trial. Lancet 2004; 364: 2188-2195.
42. Cunliffe WJ, Meynadier J, Alirezai M, et al. Is combined oral and topical therapy better than oral therapy alone in patients with moderate to moderately severe acne vulgaris? A comparison of the efficacy and safety of lymecycline plus adapalene gel 0.1%, versus lymecycline plus gel vehicle. J Am Acad Dermatol 2003; 49: suppl 2, 18-26.
43. Meynadier J, Alirezai M. Systemic antibiotics for acne. Dermatology 1998; 196: 135-139.
44. Eady EA. Bacterial resistance in acne. Dermatology 1998; 196(1): 59-66
45. Thielitz A, Helmdach M, Röpke E-M, Gollnick H. Lipid analysis of follicular casts from cyanoacrylate strips as a new method for studying therapeutic effects of antiacne, agents. Br J Dermatol 2001; 145(1): 19-27.
46. Graupe K, Cunliffe W, Gollinick H, et al. Efficacy and safety of topical azelaic acid (20% cream): an overview of results from European clinical trials and experimental reports. Cutis 1996; 57: suppl 1, 13-19.
47. Koulianos GT. Treatment of acne with oral contraceptives: criteria for pill selection. Cutis 2000; 66: 281-286.
48. Beylot C, Doutre MS, Beylot-Barry M. Oral contraceptives and cyproterone acetate in female acne treatment. Dermatology 1998; 196: 148-152.
49. Vexiau P, Husson C, Chivot M, et al. Androgen excess in women with acne alone compared with women with acne and/or hirsutism. J Invest Dermatol 1990; 94: 279-283.
50. Thiboutot D. Endocrinological evaluation and hormonal therapy for women with difficult acne. J Eur Acad Dermatol Venereol 2001; 15: suppl 3, 57-61.
51. Shaw JC. Low-dose adjunctive spironolactone in the treatment of acne in a retrospective analysis of 85 consecutively treated patients. J Am Acad Dermatol 2000; 43: 498-502.
52. Newton JN, Mellon E, Klassen A, et al. The effectiveness of acne treatment: an assessment by patients of the outcome of therapy. Br J Dermatol 1997; 137. 563-567.
53. Layton AM, Knaggs H, Taylor H, et al. Isotretinoin for acne vulgaris - 10 years later: a safe and successful treatment. Br J Dermatol 1993; 129: 292-296.
54. White GM, Yao J, Wolde-Tsadik G. Recurrence rates after one course of isotretinoin. Arch Dermatol 1998; 134: 376-378.
55. Mitchell AA, Van Bennekom CM, Louik C. A pregnancy prevention program in women of childbearing age receiving isotretinoin. N Engl J Med 1995; 333: 101-106.
56. Jick S, Kremers H, Vasilakis-Scaramozza C. Isotretinoin use and risk of depression, psychotic symptoms, suicide and attempted suicide. Arch Dermatol 2000; 136: 1231-1236.
57. Jacobs DG, Deutsch NL, Brewer M. Suicide, depression, and isotretinoin: is there a causal risk? J Am Acad Dermatol 2001; 45: S168-S175.
58. Wysowaski DK, Pitts M, Beitz J. An analysis of reports of depression and suicide in patients treated with isotretinoin. J Am Acad Dermatol 2001; 45: 515-519.
59. Meigel WN. How safe is oral isotretinoin? Dermatology 1997; 195: suppl 1, 22-28.
60. Margolis D, Attie M, Leyden J. Effects of isotretinoin on bone mineralization during routine therapy with isotretinoin for acne vulgaris. Arch Dermatol 1996; 132: 769-774.
61. Leachman SA, Insogna KL, Katz L, et al. Bone densities in patients receiving isotretinoin for cystic acne. Arch Dermatol 1999; 135: 961-965.
62. Di Giovanna JJ. Systemic retinoid therapy. Dermatol Clin 2001; 19: 161-167.
63. Cunliffe W, van de Kerkhof P, Caputo R, et al. Roaccutane treatment guidelines: results of an international survey. Dermatology 1997; 194: 351-357.
64. Ortonne JP. Oral isotretinoin treatment policy. Do we all agree? Dermatology 1997; 195: suppl 1, 34-40.